Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-1496 · 1 trial · 2 indications
Dose-limiting toxicities (DLTs) are any adverse events that are not clearly related to disease progression including Grade 4 neutropenia, Grade 3 or 4 febrile neutropenia, thrombocytopenic bleeding or Grade 4 thrombocytopenia, and any Grade 3 or 4 non hematologic toxicity. An adverse event (AE) is any unfavorable and unintended change in the structure and function (Clinical AE) or chemistry (Laboratory AE) of the body temporally associated with the use of study product, whether or not considered related to the use of the product.
This is a measure of the number of participants who experienced any adverse event (AE) while on study.
| Arm | Type | Description |
|---|---|---|
| MK-1496 20 mg (21-Day Cycle) | EXPERIMENTAL | Participants receiving MK-1496 20 mg on Day 1 of each 21-day cycle |
| MK-1496 40 mg (21-Day Cycle) | EXPERIMENTAL | Participants receiving MK-1496 40 mg on Day 1 of each 21-day cycle |
| MK-1496 80 mg (21-Day Cycle) | EXPERIMENTAL | Participants receiving MK-1496 80 mg on Day 1 of each 21-day cycle |
| MK-1496 120 mg (21-Day Cycle) | EXPERIMENTAL | Participants receiving MK-1496 120 mg on Day 1 of each 21-day cycle |
| MK-1496 20 mg (28-Day Cycle) | EXPERIMENTAL | Participants receiving MK-1496 20 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle |
| MK-1496 40 mg (28-Day Cycle) | EXPERIMENTAL | Participants receiving MK-1496 40 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle |
| MK-1496 80 mg (28-Day Cycle) | EXPERIMENTAL | Participants receiving MK-1496 80 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle |
| MK-1496 100 mg (28-Day Cycle) | EXPERIMENTAL | Participants receiving MK-1496 100 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle |
| MK-1496 120 mg (28-Day Cycle) | EXPERIMENTAL | Participants receiving MK-1496 120 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle |
| Name | Type | Description |
|---|---|---|
| MK-1496 | DRUG | MK-1496 (20 to 120 mg), orally, administered on Day 1 of each 21-day cycle |
Inclusion Criteria * Participant must have a histologically-confirmed metastatic or locally advanced solid tumor that has failed to respond to standard therapy, progressed despite standard therapy, or for which standard therapy does not exist. * Participant must have Performance Status 0 or 1. * Pa...
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | Luspatercept, Fedratinib, BMS-986158 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, ABBV-744, IMGN632 |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE3 | Elritercept |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Incyte Corporation | INCY | 8 | PHASE2 | Ruxolitinib, INCB160058, INCB057643, INCA033989, INCA036978 |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Momelotinib |
| Eli Lilly and Company | LLY | 2 | PHASE1 | LY3410738, LY5830966 |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Damora Therapeutics, Inc. | DMRA | 2 | PHASE2 | GB2064, DMR-001 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE1 | Revumenib |
MK-1496 is an investigational small molecule drug being developed by Merck & Company, Inc. for the treatment of neoplasms, including advanced solid tumors. It is designed as an inhibitor of PLK1 and has been studied in a Phase 1 clinical trial. MK-1496 has not been approved by the FDA and remains in clinical development.
MK-1496 targets PLK1, also known as polo-like kinase 1. It acts as an inhibitor of this molecular target. PLK1 is involved in cell cycle regulation, and inhibiting it is being explored as an anticancer strategy in oncology. MK-1496 is a small molecule developed by Merck for advanced solid tumors.
MK-1496 is made by Merck & Company, Inc., which trades under the ticker symbol MRK. Merck is the developer of this investigational small molecule PLK1 inhibitor. The company has conducted clinical testing of MK-1496 in patients with advanced solid tumors.
MK-1496 is in Phase 1 clinical development. It has been evaluated in a single completed Phase 1 trial. The drug is investigational and has not been approved by the FDA for any indication. Merck & Company, Inc. is the developer.
MK-1496 has been studied in one clinical trial, NCT00880568, titled Phase I Study of MK-1496 in Patients With Advanced Solid Tumor (MK-1496-002 AM 4). This Phase 1 trial is completed and enrolled 27 participants with malignant neoplasms. It was a controlled study without randomization or double-blinding.